Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,357 other S bills in the 117th — cohort avg 38d
Disease X Act This bill establishes a program to develop vaccines, diagnostics, and other medical countermeasures for unknown viral threats. Specifically, the Biomedical Advanced Research and Development Authority must carry out the program in consultation with the Public Health Emergency Medical Countermeasure Enterprise, which coordinates efforts related to medical countermeasures within the Department of Health and Human Services (HHS) and in cooperation with interagency partners. Additionally, the program must prioritize equity and accessibility in the development of the medical countermeasures. The bill also allows HHS to support domestic research, development, and manufacturing of medical countermeasures under the program through grants, contracts, and cooperative agreements.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (7)
2023 · fourth_quarter · Medical/Disease Research/Clinical Labs
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
US S 2640 Disease X Act 2023, viral surveillance in general sequencing as it relates to discovery of Disease X, development of medical counter-measures Oversight of Lab Developed Tests, express legislative authority
Client expense: $75,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Medical/Disease Research/Clinical Labs
US S 2640 Disease X Act 2023, viral surveillance in general sequencing as it relates to discovery of Disease X, development of medical counter-measures Oversight of Lab Developed Tests, express legislative authority
Client expense: $90,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Medical/Disease Research/Clinical Labs
US S 2640 Disease X Act 2023, viral surveillance in general sequencing as it relates to discovery of Disease X, development of medical counter-measures
Client expense: $130,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
S. 3799 PREVENT Pandemics Act; Pandemic Preparedness Funding; COVID-19 Response and COVID-19 Therapeutics Procurement; S. 2640 Disease X Act; S. 3258/H.R. 6025 Flu Vaccine Act; H.R. 2617, Consolidated Appropriations Act for FY 2023
Client expense: $140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
2022 · fourth_quarter · Health Issues
Drug Pricing Reform Domestic Manufacturing Medicare implications on biosimilars Appropriations pertaining to FDA inspections and American Made preferences HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act, ASP+8 H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act H.R. 7400 /S. 3991 American Made Pharmaceuticals Act Biosimilar Patient and Provider Education (including Part D) FDA foreign inspections S. 3799 PREVENT Pandemics Act ASPR/BARDA funding and policy H.R. 2870 Essential Medicine Strategic Stockpile Act (EMSSA) H.R. 5376 Inflation Reduction Act
Client expense: $275,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
2022 · third_quarter · Health Issues
S. 3799 PREVENT Pandemics Act; Pandemic Preparedness Funding; COVID-19 Response and COVID-19 Therapeutics Procurement; S. 2640 Disease X Act; S. 3258/H.R. 6025 Flu Vaccine Act; FY 2023 Labor-HHS Appropriations; H.R. 5376, Inflation Reduction Act
Client expense: $150,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
2022 · third_quarter · Health Issues
Build Back Better Act Drug Pricing Reform ASP+8 for biosimilars Domestic Manufacturing Medicare implications on biosimilars Appropriations pertaining to FDA inspections and American Made preferences HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act H.R. 7400 /S. 3991 American Made Pharmaceuticals Act Biosimilar Patient and Provider Education (including Part D) FDA foreign inspections S. 3799 PREVENT Pandemics Act ASPR/BARDA funding and policy H.R. 2870 Essential Medicine Strategic Stockpile Act (EMSSA) H.R. 5376 Inflation Reduction Act
Client expense: $250,000 · Firm income: Not reported
2022 · second_quarter · Health Issues
S. 3799 PREVENT Pandemics Act; Pandemic Preparedness Funding; COVID-19 Response and COVID-19 Therapeutics Procurement; S. 2640 Disease X Act; S. 3258/H.R. 6025 Flu Vaccine Act; FY 2023 Labor-HHS Appropriations.
Client expense: $140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
2022 · second_quarter · Health Issues
S. 2640 - Disease X Act; Pandemic and Covid-19 preparedness; S. 3799 PREVENT Pandemics Act; CURES 2.0 legislation; H.R. 5585 - ARPA-H Act.
Client expense: Not reported · Firm income: $20,000
Government targets: SENATE
2022 · second_quarter · Health Issues
Build Back Better Act Drug Pricing Reform ASP+8 for biosimilars Domestic Manufacturing Medicare implications on biosimilars Appropriations pertaining to FDA inspections HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act American Made Pharmaceutical Act
Client expense: $250,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
2022 · first_quarter · Health Issues
S. 2640 - Disease X Act; Pandemic and Covid-19 preparedness; S. 3799 PREVENT Pandemics Act.
Client expense: Not reported · Firm income: $10,000
Government targets: SENATE
2022 · first_quarter · Health Issues
S. 3799 PREVENT Pandemics Act; H.R. 2471 Consolidated Appropriations Act, COVID Supplemental Appropriations Act; Pandemic Preparedness Funding; COVID-19 Response and COVID-9 Therapeutics Procurement; S. 2640 Disease X Act; S. 3258/H.R. 6025 Flu Vaccine Act.
Client expense: $170,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
2022 · first_quarter · Health Issues
Strengthening public health infrastructure, workforce and data in preparation for the next pandemic; Tracking Pathogens Act (S. 3534); PREVENT Pandemics Act (S. 3799); Disease X Act (S. 2640); Newborn Screening Saves Lives Reauthorization Act (H.R. 482).
Client expense: Not reported · Firm income: $20,000
Education and advocacy supporting the mission of the Coalition for Epidemic Preparedness Innovations (CEPI), including development of vaccines for emerging diseases to help prevent and respond to epidemics and pandemics and strengthen global health security. H.R.2118, Securing America From Epidemics Act, Sec. 3, Authorization for United States Participation H.R.4350, FY22 National Defense Authorization Act, Sec. 6427, Authorization for United States participation in the Coalition for Epidemic Preparedness Innovations H.R.4373, Department of State, Foreign Operations, and Related Programs Appropriations Act, 2022, Title 3, all provisions relating to global health programs S. 1605, FY22 National Defense Authorization Act, Sec. 6501, Authorization for United States participation in the Coalition for Epidemic Preparedness Innovations S. 2640, Disease X Act, general support for legislation S.3799, PREVENT Pandemics Act, Titles 3,4 and 5, provisions related to vaccine research and development House Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act, FY2023 Senate Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act, FY2023
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office
2022 · first_quarter · Health Issues
Build Back Better Act Drug Pricing Reform ASP+8 for biosimilars Domestic Manufacturing Medicare implications on biosimilars Appropriations pertaining to FDA inspections HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act American Made Pharmaceutical Act
Client expense: $200,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office
2022 · first_quarter · Health Issues
Funding for global health research and development; 21st Century Cures 2.0; S. 2640 - Disease X Act; Pandemic and Covid-19 preparedness
Client expense: Not reported · Firm income: Not reported
2022 · first_quarter · Budget/Appropriations
Funding for global health research and development; 21st Century Cures 2.0; S. 2640 - Disease X Act; Pandemic and Covid-19 preparedness
Client expense: Not reported · Firm income: Not reported
2021 · fourth_quarter · Health Issues
Build Back Better Act Drug Pricing ASP+8 for biosimilars Domestic Manufacturing Medicare implications on biosimilars Pass Through Status Extension Appropriations and reach out pertaining to FDA inspections HHS Supply Chain Readiness HHS Biosimilar Uptake 340B Drug Pricing Program American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act
Client expense: $160,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, White House Office
2021 · fourth_quarter · Health Issues
S. 2640, Disease X Act; S. 3258/H.R 6025, Flu Vaccine Act; Build Back Better - Prescription Drug Policy, Pandemic Preparedness Funding; COVID-19 Response and COVID-19 Therapeutics Procurements; Pandemic Preparedness.
Client expense: $120,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE
2021 · fourth_quarter · Health Issues
21st Century Cures 2.0; S. 2640 - Disease X Act; Pandemic and Covid-19 preparedness.
Client expense: Not reported · Firm income: $10,000
2021 · third_quarter · Health Issues
S.164 - Advancing Education on Biosimilars Act of 2021 Pass-Through Status Extension Medicare payments for Biosimilars Appropriations and reach out pertaining to FDA inspections HHS Supply Chain Readiness HHS Biosimilar Uptake 340B Drug Pricing Program American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act
Client expense: $130,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, White House Office
2021 · third_quarter · Health Issues
S. 2640, Disease X Act; H.Res. 601, FY 2022 Budget Resolution and Reconciliation Instructions, S. Con. Res. 14 FY 2022 Budget Resolution and Reconciliation Instructions; Prescription Policy in Budget Reconciliation; American Rescue Plan Implementation (COVID-19 Response and COVID Therapeutics Procurements), Pandemic Preparedness.
Client expense: $170,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
2021 · third_quarter · Health Issues
S. 2076, H.R. 3932 - PASTEUR Act; 21st Century Cures 2.0; S. 2640 - Disease X Act.
Client expense: Not reported · Firm income: $10,000
2021 · third_quarter · Health Issues
The Disease X Act (S. 2640) and federal funding for public health emergency preparedness.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, White House Office